Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM9AGCV)

Drug Name
N-Methylleucine Drug Info
Synonyms
N-Methyl-L-leucine; 3060-46-6; (S)-4-Methyl-2-(methylamino)pentanoic acid; N-Methylleucine; L-Leucine, N-methyl-; N-Me-Leu-OH; MeLeu; methyl-L-leucine; UNII-2YT9687ECD; 2YT9687ECD; H-ALPHA-METHYL-L-LEUCINE; AK107655; N-methyl-l-leu; Leucine, N-methyl-; AC1MCSAQ; SCHEMBL93452; AMGLY00163; CTK1A1168; MolPort-003-925-252; XJODGRWDFZVTKW-LURJTMIESA-N; ZINC160405; KS-00000J9G; FCH835634; ANW-74881; AKOS006282756; CS-W008140; ACM3060466; AJ-15591; SC-82208; KB-58630; AC-24158; AS-19192; DB-038132; TC-163626; AX8020112; X5243; ST24036190; FT-0695191
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
6951123
CAS Number
CAS 31321-74-1
TTD Drug ID
DM9AGCV

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting C-X-C motif chemokine 10 (CXCL10)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BMS-936557 DMUTS1W Immune System disease 4A01-4B41 Phase 2 [2]
NI-0801 DMRQUH4 Autoimmune diabetes 5A10 Phase 2 [3]
MDX-1100 DM0EZWI Crohn disease DD70 Phase 2 [4]
Anti-IP10 DMVRNAO Crohn disease DD70 Phase 2 [2]
JT02 DMXTKCR Inflammatory bowel disease DD72 Phase 2 [5]
NG-641 DMITVHM Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
C-X-C motif chemokine 10 (CXCL10) TTQOVYA CXL10_HUMAN Inhibitor [1]

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar;63(3):442-50.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029267)
4 A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012 Jun;64(6):1730-9.
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Clinical pipeline report, company report or official report of PsiOxus Therapeutics.